Acumen Pharmaceuticals (ABOS) 10-Q2022 Q2 Quarterly report

Content analysis

Filed: 15 Aug 22, 5:18pm

Date: August 15, 2022

/s/ Daniel O’Connell

Daniel O’Connell

President and Chief Executive Officer
(Principal Executive Officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: anti, ATM, deepen, earlyAD, macroeconomic, persist, shelf, wenamed

Removed: calculating, consolidated, expanding, invested, nil, unfavorable

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABOS transcripts

ABOS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals, Inc. (the “Company”), hereby certifies that, to the best of his knowledge:

1.	The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2022, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.	The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.